Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 55497 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Epstein-Barr Negative LymphomaDerived Cell Lines 

Description of Technology: The 

National Institutes of Health developed 

multiple lymphoid cell lines that were 

derived from patients with 

undifferentiated lymphoma of Burkitt’s 

or non-Burkitt’s type (now known as 

Burkitt and Burkitt-like lymphoma). 

Burkitt lymphoma is a highly aggressive 

B-cell lymphoma, which accounts for 

approximately half of all non Hodgkin’s 

lymphomas in children. It also occurs in 

adults, and in some patients with 

compromised immune systems, e.g., in 

patients infected with HIV. The cell 

lines have been used to advance our 

understanding of the molecular 

mechanisms of lymphomagenesis, and 

thus, can be used for the identification 

of molecular targets for drugs or other 

agents that can be developed for the 

treatment of lymphomas and other 

tumors. 

The Epstein-Barr virus (EBV) has been 

implicated in the pathogenesis of 

Burkitt lymphoma, although 

geographical variations occur. Ten out 

of sixteen cell lines derived at the NIH 

were found to be negative for EpsteinBarr virus (EBV), consistent with the 

low frequency of EBV association in this 

tumor in the USA. The cell lines were 

screened for chromosomal aberrations 

and fifteen were found to contain 

reciprocal translocation between 

chromosome 8 and 14, t(8;14). These 

exchanges involve the chromosomal 

regions on which the c-myc oncogene 

(8q24.1) and the heavy-chain 

immunoglobulin genes (14q32) reside. 

Applications: (1) Screening tool to 

identify novel genes unique to or 

overexpressed in Burkitt lymphoma; (2) 

Screen for compounds that kill tumor 

cells and represent potential therapeutic 

agents; (3) Control in screening for novel 

genes expressed or overexpressed in 

EBV + Burkitt lymphoma; (4) Control for 

therapeutic agents directed against EBV 

genes or genes induced by EBV 

Inventor: Ian Magrath (NCI) 

Publications: 1. IT Magrath, et al., 

‘‘Characterization of lymphoma-derived 

cell lines: comparison of cell lines 

positive and negative for Epstein-Barr 

virus nuclear antigen. I. Physical, 

cytogenetic, and growth 

characteristics.’’ J Natl Cancer Inst. 1980 

March; 64(3):465–476. 

2. IT Magrath, et al., ‘‘Characterization 

of lymphoma-derived cell lines: 

Comparison of cell lines positive and 

negative for Epstein-Barr virus nuclear 

antigen. II. Surface markers.’’ J Natl 

Cancer Inst. 1980 Mar; 64(3):477–483. 

Patent Status: HHS Reference No. E–

221–2006/0—Research Tool. 

Licensing Status: Available for 

licensing under a biological material 

license. 

Licensing Contact: John Stansberry, 

PhD; 301/435–5236; 

stansbej@mail.nih.gov. 

Organic Thiophosphate Antiretroviral 

Agents 

Description of Technology: The 

current technology represents a 

potentially safe and effective addition to 

the antiretroviral drug combinations 

used for treatment of HIV infection. 

Amifostine, phosphonol and functional 

derivatives thereof are available for 

licensing and commercial development 

for use as antiretroviral drugs. These 

organic thiophosphate reducing agents 

inhibit HIV viral growth and protein 

expression in HIV-infected human 

white blood cells without destroying the 

cells. The compounds described in this 

technology block growth of HIV by a 

mechanism that is dependent on the 

level of aminothiol reducing agent in 

the cellular environment. In addition, a 

range of effective doses and methods for 

oral administration of the available 

organic thiophosphates is provided. 

Applications: (1) Novel therapeutics 

for the treatment of HIV infection; (2) 

Safe and effective addition to the drug 

combinations currently used to treat 

HIV/AIDS. 

Market: (1) Nearly 40.3 million people 

living with HIV worldwide, including 

approximately 2.0 million people in 

North America and Europe; (2) AntiHIV/AIDS therapeutics experience 

accelerated market acceptance and draw 

revenues of approximately $240 million 

to $1 billion. 

Development Status: Preclinical data 

is available at this time. 

Inventors: Miriam C. Poirier (NCI), 

Gene M. Shearer (NCI), et al. 

Related Publications: 1. T Kalebic and 

PS Schein. Organic thiophosphate WR–

151327 suppresses expression of HIV in 

chronically infected cells. AIDS Res 

Hum Retroviruses. 1994 Jun; 10(6):727–

733. 

2. JL Rossio, MT Esser, K 

Suryanarayana, DK Schneider, JW Bess 

Jr, GM Vasquez, TA Wiltrout, E 

Chertova, MK Grimes, Q Sattentau, LO 

Arthur, LE Henderson, JD Lifson. 

Inactivation of human 

immunodeficiency virus type 1 

infectivity with preservation of 

conformational and functional integrity 

of virion surface proteins. J Virol. 1998 

Oct; 72(10):7992–8001. 

3. CF Perno, R Yarchoan, DA Cooney, 

NR Hartman, S Gartner, M Popovic, Z 

Hao, TL Gerrard, YA Wilson, DG Johns, 

et al. Inhibition of human 

immunodeficiency virus (HIV–1/HTLV–

IIIba–L) replication in fresh and 

cultured human peripheral blood 

monocytes/macrophages by 

azidothymidine and related 2′,3′- 

dideoxynucleosides. J Exp Med. 1988 

Sep 1; 168(3):1111–1125. 

4. LS Clark, RJ Albertini, JA Nicklas. 

The aminothiol WR–1065 protects T 

lymphocytes from ionizing radiationinduced deletions of the HPRT gene. 

Cancer Epidemiol Biomarkers Prev. 

1997 Dec; 6(12):1033–1037. 

5. NP Nguyen, B Levinson, S Dutta, U 

Karlsson, KC Kelly, J Dowell, A Ludin, 

S Sallah. Amifostine and curative intent 

chemoradiation for compromised cancer 

patients. Anticancer Res. 2003 Mar–Apr; 

23(2C):1649–1656. 

Patent Status: U.S. Provisional 

Application No. 60/792,431 filed 17 Apr 

2006 (HHS Reference No. E–017–2006/ 

0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Sally Hu, PhD; 

301/435–5606; HuS@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute 

Laboratory of Cellular Carcinogenesis 

and Tumor Promotion is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 


sroberts on PROD1PC70 with NOTICES
55498 Federal Register / Vol. 71, No. 184 / Friday, September 22, 2006 / Notices 

commercialize these organic 

thiophosphate antiretroviral agents. 

Please contact Betty Tong, PhD at 301/ 

594–4263 or tongb@mail.nih.gov for 

more information. 

Dated: September 18, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–8082 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

H—Clinical Groups, NCI Subcommittee H—

Clinical Trials. 

Date: October 24–25, 2006. 

Time: 7 p.m. to 2 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., MIRAGE I & II, 

Washington, DC 20007. 

Contact Person: Timothy C. Meeker, MD, 

PhD, Scientific Review Administrator, 

Resources and Training Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, 6116 Executive Boulevard, 

Room 8103, Bethesda, MD 20892, (301) 594–

1279, meekert@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NIH Small 

Grants for Cancer Epidemiology and Cancer 

Prevention. 

Date: November 7–9, 2006. 

Time: 8 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Irina Gordienko, PhD., 

Scientific Review Administrator, Scientific 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Blvd., Rm. 

7073, Bethesda, MD 20892, 301–594–1566, 

gordienkoiv@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 15, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8087 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR 

Topics 210 and 213. 

Date: October 26, 2006. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: NIH Events Management, Executive 

Plaza North, 6130 Executive Boulevard, 

Conference Room C, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Marvin L. Salin, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, 6116 Executive 

Boulevard, Room 7073, MSC8329, Bethesda, 

MD 20892–8329, 301–496–0694, 

msalin@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 15, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8092 Filed 9–21–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552(b)(c)(4) and 552b(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute of 

Alcohol Abuse and Alcoholism Initial 

Review Group, Biomedical Research Review 

Subcommittee. 

Date: October 12–13, 2006. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Sathasiva B. Kandasamy, 

Phd, Scientific Review Administrator, Office 

of Scientific Affairs, National Institute on 

Alcohol Abuse & Alcoholism, Extramural 

Review Branch, 5635 Fishers Lane, Bethesda, 

MD 20892–9304, (301) 443–2861, 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants, 

National Institutes of Health, HHS) 


sroberts on PROD1PC70 with NOTICES